EPIX insider transaction filings
ESSA Pharma Inc. — 36 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-10-15. Screen EPIX transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for EPIX between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — ESSA Pharma Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-10-15 | 4 | Wood David S. — Chief Financial Officer | Disposition to issuer (D): 33,343 | EDGAR |
| 2025-10-15 | 4 | Requadt Scott — Director | Disposition to issuer (D): 30,002 | EDGAR |
| 2025-10-15 | 4 | Thorell Marella — Director | Disposition to issuer (D): 2,881 | EDGAR |
| 2025-10-15 | 4 | Martin John Alexander — Director | Disposition to issuer (D): 14,299 | EDGAR |
| 2025-10-15 | 4 | Parkinson David Ross — President and CEO, Director | Disposition to issuer (D): 65,675 | EDGAR |
| 2025-10-15 | 4 | Glickman Richard M — Director | Disposition to issuer (D): 43,240 | EDGAR |
| 2025-10-15 | 4 | BERGER FRANKLIN M — Director | Disposition to issuer (D): 784,404 | EDGAR |
| 2025-10-14 | 4 | BVF PARTNERS L P/IL — 10% owner BIOTECHNOLOGY VALUE FUND L P — 10% owner BVF I GP LLC — 10% owner BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC — 10% owner BVF INC/IL — 10% owner LAMPERT MARK N — 10% owner | Code (U): 6,194,145 · Code (U): 4,726,743 · Code (U): 560,797 | EDGAR |
| 2025-08-07 | 4 | BVF PARTNERS L P/IL — 10% owner BIOTECHNOLOGY VALUE FUND L P — 10% owner BVF I GP LLC — 10% owner BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC — 10% owner BVF INC/IL — 10% owner LAMPERT MARK N — 10% owner | Option exercise/expiry (X): 1,481,634 @ $0.00 · Option exercise/expiry (X): 1,235,030 @ $0.00 · Option exercise/expiry (X): 203,336 @ $0.00 · Sale (S): 79 @ $1.88 · Sale (S): 66 @ $1.88 · Sale (S): 11 @ $1.88 · +3 more | EDGAR |
| 2024-11-05 | 4 | BIOTECH GROWTH N V — 10% owner BB BIOTECH AG — 10% owner | Sale (S): 2,000,000 @ $1.53 · Sale (S): 2,000,000 @ $1.53 · Sale (S): 2,000,000 @ $1.53 · Sale (S): 1,879,583 @ $1.51 | EDGAR |
| 2024-10-07 | 4 | Virsik Peter — Chief Operating Officer | Sale (S): 694 @ $6.03 | EDGAR |
| 2024-09-09 | 4 | Virsik Peter — Chief Operating Officer | Sale (S): 694 @ $6 | EDGAR |
| 2024-09-03 | 4 | Virsik Peter — Chief Operating Officer | Sale (S): 2,082 @ $6.03 | EDGAR |
| 2024-05-06 | 4 | Virsik Peter — Chief Operating Officer | Sale (S): 694 @ $6.95 | EDGAR |
| 2024-04-25 | 4 | Glickman Richard M — Director | Option exercise (M): 3,750 @ $4.90 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2024-04-05 | 4 | Virsik Peter — Chief Operating Officer | Sale (S): 694 @ $7.94 | EDGAR |
| 2024-03-28 | 4 | Thorell Marella — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Sollis Gary — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Requadt Scott — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Merendino Lauren — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Kantoff Philip W. — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Wood David S. — Chief Financial Officer | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Virsik Peter — Chief Operating Officer | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Cesano Alessandra — Chief Medical Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Martin John Alexander — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Parkinson David Ross — Chief Executive Officer, Director | Grant/award (A): 350,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Glickman Richard M — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | BERGER FRANKLIN M — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | ZWEIFACH SANFORD S — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Virsik Peter — Chief Operating Officer | Sale (S): 694 @ $8.98 | EDGAR |
| 2024-02-07 | 4 | Virsik Peter — Chief Operating Officer | Option exercise (M): 72,782 @ $3.23 · Sale (S): 72,782 @ $10.29 · Option exercise (M): 72,782 (derivative) @ $0 | EDGAR |
| 2024-02-06 | 4 | Virsik Peter — Chief Operating Officer | Sale (S): 694 @ $9.25 · Option exercise (M): 500 @ $3.23 · Sale (S): 500 @ $10.04 · Option exercise (M): 500 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Virsik Peter — Chief Operating Officer | Option exercise (M): 1,718 @ $3.23 · Sale (S): 1,718 @ $10.01 · Option exercise (M): 1,718 (derivative) @ $0 | EDGAR |
| 2024-01-16 | 4 | Requadt Scott — Director | Other (J): 17,502 @ $0 · Other (J): 12,500 @ $0 | EDGAR |
| 2024-01-08 | 4 | Virsik Peter — Chief Operating Officer | Sale (S): 699 @ $6.11 | EDGAR |
| 2023-12-18 | 4 | Parkinson David Ross — Chief Executive Officer, Director | Purchase (P): 9,223 @ $2.30 | EDGAR |
Recent 8-K events — ESSA Pharma Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-10-09 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-06 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-03 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-09-30 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-25 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-31 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EPIX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →